News | Cath Lab | April 17, 2017

Study Finds Significant Variability in Doctors' Angioplasty Death Rates

Judging doctors on mortality data may not give the full picture

Study Finds Significant Variability in Doctors Angioplasty Death Rates

April 17, 2017 — Some doctors have higher or lower than expected death rates from coronary angioplasty procedures, also known as percutaneous coronary intervention (PCI). However, doctors should not be judged solely on the rate of patients who die from the procedure, as the rate is highly variable over time, according to a recent study in JACC: Cardiovascular Interventions

PCI is a nonsurgical procedure that improves blood flow to the heart. It requires cardiac catheterization, which is the insertion of a catheter tube and injection of contrast dye into the coronary arteries. Doctors use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque. PCI may be used to relieve symptoms of coronary heart disease or to reduce heart damage during or after a heart attack.

The new study analyzed data from the National Cardiovascular Data Registry CathPCI Registry to determine how many physicians had mortality rates outside the expected norm. The study included 3,760 doctors who performed 2,343,693 PCI procedures. The researchers adjusted for a number of factors, including how sick patients were.

The researchers found a small but significant number of doctors (6.5 percent) with mortality rates above what would be expected, as well as a small but significant number (4.1 percent) with mortality rates below what would be expected.

PCI mortality rates for individual doctors may be useful for both doctors and hospitals to assess and monitor their care and see where they need improvement, said Jacob Doll, M.D., a cardiologist at the University of Washington in Seattle and lead author of the study. “It could drive hospitals and doctors to further improve the safety of a procedure that’s already low-risk. However, I don’t see this measure as ready for widespread use as a publicly reported measure or to influence payment.”

A limitation with assessing mortality rates is that it is rare for patients to die from PCI — for every 100 procedures, only slightly more than 1 percent of patients die, and for elective PCI, death is very rare.

“Any given doctor may have only one or two deaths a year — some years just by chance you may have two or four, which seems like a lot, and the next year, you may have none. This may be further confounded by the low number of deaths that can be ascribed to the procedure, and makes it challenging to know whether these differences are actually due to the care received,” Doll said.

A number of factors affect a physician’s PCI mortality rate, Doll said. 

Because procedures performed on sicker patients often have higher mortality rates, Doll and colleagues took this into account, by using what is called a risk standardized mortality rate (RSMR).

“This helps us interpret the results to determine who really has a higher-than-expected morality rate, and who has a higher actual mortality rate because they take care of sicker patients,” he said.

In an editorial accompanying the study, Michael McDaniel, M.D., an assistant professor of medicine at Emory University School of Medicine in Atlanta, said that doctors concerned about their mortality rate being reported publicly may avoid treating the highest-risk patients.

 

Related NCDR CathPCI Registry articles:

• Radial Access, Same-Day Cardiac Procedure Could Save $300 Million Annually

• New Report Highlights National Trends in Heart Disease Treatments

• Better Prognosis for Some PCI Patients When Operators Perform More Procedures
 

 

For more information: www.interventions.onlinejacc.org

Related Content

Among high-risk, chronic, coronary patients who undergo angioplasty, there were no additional benefits from ticagrelor compared to the current standard of care clopidogrel. #AHA #AHA20 #AHA2020
News | Cath Lab | November 16, 2020
November 16, 2020 — The use of the more potent antiplatelet medication ticagrelor (Brilinta) was not superior to clop
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab | October 18, 2020
October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benef
A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin capped fibrous atheroma (TCFA). #TCTconnect #TCT2020

A longitudinal vessel assessment may demonstrate co-existence of multiple plaque morphologies on OCT, including superficial calcification with thrombus, healed plaque, plaque rupture, lipidic plaque with a thin cap fibro-atheroma (TCFA).

News | Cath Lab | October 18, 2020
October 18, 2020 – Data from the...
The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions. #TCT2-0

The DISRUPT CAD III study showed intravascular lithoplasty from Shockwave Medical was effective in breaking up calcified coronary lesions.

Feature | Cath Lab | October 16, 2020
October 15, 2020 — Shockwave Medical's Intravascular Lithotripsy (IVL) system to treat severely calcified coronary ar
Videos | Cath Lab | October 16, 2020
This is an example pf the Shockwave Medical Intravascular Lithotripsy (IVL) catheter system designed to break up heav
Videos | Cath Lab | July 15, 2020
Richard Botto, CVT, RCSA, chief cardiovascular technologist, division of cardiology, cardiac cath lab, offers an over
Videos | Cath Lab | July 13, 2020
The Vieussens’ arterial ring (VAR) is a connection between the conus artery and the left anterior descending (LAD) co
News | Cath Lab | July 06, 2020
July 6, 2020 — Black patients who undergo percutaneous coronary intervention (PCI) are at an increased risk for major